Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 3/20 | 0.47 |
| ▸ | PGK2 | P07205 | 3/20 | 0.47 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14769117 | 0.78 | PGK1 (0.48) | PGK1PGK2 | |
| SCHEMBL9105896 | 0.77 | FDPS (0.49) | PGK1PGK2KDM4ERAB9A | |
| SCHEMBL14769151 | 0.77 | PGK1 (0.47) | PGK1PGK2DAO | |
| SCHEMBL14771822 | 0.77 | PGK1 (0.43) | PGK1PGK2 | |
| Hydrochloric Acid SCHEMBL2637290 | 0.76 | PGK1 (0.46) | PGK1PGK2 | |
| Butane SCHEMBL4025883 | 0.75 | FDPS (0.44) | PGK1PGK2KDM4ERAB9A | |
| SCHEMBL17017353 | 0.75 | KDM4E (0.54) | CCR1CCR5CCR8HDAC6KDM4E | |
| SCHEMBL9129688 | 0.74 | CA12 (0.46) | KDM4ERAB9A | |
| SCHEMBL14769155 | 0.73 | PGK1 (0.47) | PGK1PGK2 | |
| SCHEMBL17007182 | 0.73 | KMT2A (0.49) | PGK1PGK2KDM4EDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | BAYLOR COLLEGE OF MEDICINE (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | DDX18, FPR1, DCXR | PGK1 1613/4885PGK2 1758/4885CCR1 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.